[
{
	"page":"ENAS5269_1.0.0.0",
	"text":"1.0.0.0 Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-‍Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth De Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Central venous access in oncology: ESMO Clinical Practice Guidelines Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, Pinto D and Cardoso F, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26 (Suppl 5):v152–68 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍26/‍suppl_5/v152.full.pdf+html Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Peterson DE, Boers-‍‍Doets CB, Bensadoun RJ and Herrstedt J, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26 (Suppl 5):v139–51 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍26/‍suppl_5/v139.full.pdf+html Prevention of chemotherapy-‍‍ and radiotherapy-‍‍induced nausea and vomiting and of nausea and vomiting in advanced cancer patients: 2016 MASCC and ESMO guideline update Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-‍‍Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D and van der Wetering M, on behalf of the participants of the MASCC-‍‍ESMO Consensus Conference Ann Oncol 2016; 27 (Suppl 5): v119–33 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍27/‍suppl_5/v119.full.pdf+html Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Mandalà M, Falanga A and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2011;22(Suppl 6):vi85–92 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍22/‍suppl_6/vi85.full.pdf+html Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2012;23(Suppl 7):vii155–66 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍23/‍suppl_7/vii155.full.pdf+html Management of chemotherapy extravasation: ESMO-‍EONS Clinical Practice Guidelines Pérez Fidalgo JA, García Fabregat L, Cervantes A, Marguiles A, Vidall C and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2012;23(Suppl 7):vii167–73 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍23/‍suppl_7/vii167.full.pdf+html Management of febrile neutropaenia: ESMO Clinical Practice Guidelines Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M and Herrstedt J, on behalf of the ESMO Guidelines Committee Ann Oncol 2016; 27 (Suppl 5): v111–8 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍27/‍suppl_5/v111.full.pdf+html Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines Roselló S, Blasco I, García Fabregat L, Cervantes A and Jordan K, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv100–18 https://​academic.oup.com/​annonc/​article-pdf/​28/​suppl_4/​iv100/18528215/​mdx216.pdf   Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J and Jordan K, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv119–42 https://​academic.oup.com/​annonc/​article-pdf/​28/​suppl_4/​iv119/​3958159/​mdx225.pdf ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPGs) and consensus statements on various aspects of supportive care for your patients. Key content includes central venous access in oncology; prevention of chemotherapy-‍‍ and radiotherapy induced nausea and vomiting; and management of febrile neutropenia, mucositis, venous thromboembolism, extravasation associated with the administration of chemotherapeutic agents and of the cardiotoxic effects of chemotherapy and radiotherapy. The ESMO CPG and consensus statements covered in this booklet are intended to provide you with a set of recommendations for the best standards of supportive care, using evidence-‍‍based medicine. Implementation of ESMO CPG and consensus statements facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on supportive care in cancer. Please visit http://www.esmo.org or http://oncologypro.esmo.org to view the full guidelines."
},
{
	"page":"ENAS5269_2.0.0.0",
	"text":"2.0.0.0 Introduction Febrile neutropaenia (FN), defined as an oral temperature of > 38.3°C or two consecutive readings of > 38.0°C for 2 hours and an absolute neutrophil count (ANC) < 0.5 x 109/L, or expected to fall below 0.5 x 109/L, is a frequent complication of cancer chemotherapy (ChT) Factors increasing the risk of FN and its complications include: older age, advanced disease, history of prior FN, no antibiotic prophylaxis or granulocyte-‍colony stimulating factor (G-CSF) use, mucositis, poor performance status (PS) and/‍or cardiovascular disease These guidelines should be used alongside appropriate local antimicrobial policies adapted to the centre’s epidemiology"
},
{
	"page":"ENAS5269_3.0.0.0",
	"text":"3.0.0.0 Chemoprophylaxis In general, the use of antimicrobials, including fluoroquinolones, in prophylaxis is discouraged European Organisation for Research and Treatment of Cancer (EORTC) and American Society of Clinical Oncology (ASCO) guidelines recommend the restriction of antibacterial prophylaxis to patients at high risk for FN Some guidelines recommend avoidance of antimicrobial prophylaxis, while others still recommend use of ciprofloxacin or levofloxacin in cancer patients undergoing intensive chemotherapy"
},
{
	"page":"ENAS5269_4.1.0.0",
	"text":"4.0.0.0 Indications for primary prophylaxis with G-CSF 4.1.0.0 Overview INDICATIONS FOR PRIMARY PROPHYLAXIS OF FN WITH G-CSF Primary prophylaxis (administered immediately after cycle 1 of ChT) with G-CSF (filgrastim, pegfilgrastim or European Medicines Agency (EMA)-‍/Food and Drug Administration (FDA)-‍approved biosimilars) is recommended if the risk of FN is > 20% for all planned cycles of treatment, as shown in the figure here For patients with an intermediate FN risk (10–20%), age and existing co-‍morbidities are important considerations in prophylaxis decisions G-CSF can also be considered for patients with reduced bone marrow reserve due to extensive radiotherapy or those neutropaenic in the context of human immunodeficiency virus (HIV) infection Secondary prophylaxis (i.e. G-CSF given for a course of ChT following a course with FN) is indicated if dose reduction below threshold or delay of ChT is not desirable (e.g. treatment with a curative intent) There are few complications associated with G-CSF administration; the most common adverse effect is minor or moderate bone pain that can usually be managed with standard analgesics"
},
{
	"page":"ENAS5269_4.3.0.0",
	"text":"Dose, schedule and route of application of G-CSF and pegfilgrastim 4.3.0.0. Dose, sched. & route of G-CSF & pegfilgrastim The recommended doses and schedules are G-CSF 5 μg/‍kg/‍day subcutaneously (SC) 24–72 hours after the last day of ChT until sufficient/‍stable post-‍nadir ANC recovery (achieving target ANC > 10 × 109/L is not necessary) Pegfilgrastim (SC) as a single 100 μg/kg dose (individualised) or a 6 mg total dose (general approach) Filgrastim 5 μg/‍kg/‍day for approximately 10 days There are no adequate data to support reduced numbers of days or alternate days of G-CSF, or for use on day 1 instead of day 2"
},
{
	"page":"ENAS5269_5.1.0.0",
	"text":"5.0.0.0 Management of FN 5.1.0.0 Patient education and local policies Outpatients should be educated to monitor their symptoms, including body temperature, and should be provided with clear written instructions on when and how to contact the appropriate service in the event of concerns Effective written local policies are essential to ensure a rapid response whenever FN is suspected Protocols for the management of FN in patients presenting to the Emergency Department should be in place The first administration of therapy should be given in the hospital within 1 hour from the admission of a patient with FN Local epidemiological knowledge is crucial"
},
{
	"page":"ENAS5269_5.2.0.0",
	"text":"5.2.0.0 Initial assessment and investigations A detailed history should include the nature of the ChT, prior prophylactic antibiotics, concomitant steroid use, recent surgical procedures and presence of allergies Investigation of past positive microbiology, in particular previous presence of antibiotic-resistant organisms or bacteraemia, is recommended An initial assessment of circulatory and respiratory function, as shown in the table below, with vigorous resuscitation where necessary, should be followed by careful examination for potential foci of infection INITIAL ASSESSMENT AND INVESTIGATIONS 1 Note presence of indwelling IV catheters 2 Symptoms or signs suggesting an infection focus: Respiratory system Gastrointestinal tract Skin Perineal region/‍genitourinary discharges Oropharynx Central nervous system 3 Knowledge of previous positive microbiology results by checking clinical records 4 Routine investigations: Urgent blood testing to assess bone marrow, renal and liver function Coagulation screen C-‍reactive protein Blood cultures (minimum of two sets) including cultures from indwelling IV catheter Urinalysis and culture* Sputum microscopy and culture* Stool microscopy and culture* Skin lesion (aspirate/‍biopsy/‍swab) Chest radiograph 5 Further investigations (profound/‍prolonged neutropaenia/following allografts) High-‍resolution chest CT (if pyrexial despite 72 hours of appropriate antibiotics) Broncho-‍alveolar lavage *Urinalysis, sputum and stool cultures ONLY in case of suspected focus of infection at these sites CT, computed tomography; IV, intravenous Signs and symptoms of infection in neutropaenic patients can be minimal, particularly in those receiving corticosteroids, or in elderly patients Vigilance is required in patients at risk of FN who present unwell, are hypotensive (compared with the known previous blood pressure readings) and have a low grade temperature or are afebrile, as this may be an indication of Gram-‍negative septicaemia, requiring prompt treatment Urgent full blood counts are crucial in guiding early management Two sets of blood cultures from a peripheral vein and any indwelling venous catheters should be taken along with specimens for microbiological testing from any suspected sites of infection, before the prompt institution of empirical broad-‍spectrum antimicrobial therapy Urinary tract infections should be suspected, even in asymptomatic patients with a past history of such infections"
},
{
	"page":"ENAS5269_5.3.0.0",
	"text":"5.3.0.0 Outcome risk assessment The vast majority of FN cases, managed according to the algorithm here, respond promptly to empirical therapy, without major complications The prospectively validated Multinational Association of Supportive Care in Cancer (MASCC) index, as shown here, allows rapid assessment, on just a clinical basis, of the risk of a patient with FN Low-‍risk cases are those scoring ≥ 21, with a serious medical complication rate of 6% and a mortality rate of < 1% If an obvious focus of infection is apparent, antibacterials should be tailored accordingly"
},
{
	"page":"ENAS5269_5.6.1.0",
	"text":"5.6.0.0 Low-‍risk patients 5.6.1.0 Oral therapy Inpatient oral antibacterial therapy can be safely substituted for conventional intravenous (IV) treatment in some low-‍risk FN patients, namely those who are haemodynamically stable, without acute leukaemia or evidence of organ failure and without pneumonia, an indwelling venous catheter or severe soft tissue infection Combination therapy (quinolone with amoxicillin plus clavulanic acid) is preferred to single-‍agent quinolones, given the rise in Gram-‍positive FN Oral quinolone therapy should not be used in patients who have taken a quinolone antibacterial as prophylaxis Early change to oral combinations in afebrile patients after 48 hours on IV therapy is safe and preferred by many physicians Some low-‍risk patients may be treated with outpatient parenteral regimens"
},
{
	"page":"ENAS5269_5.6.2.0",
	"text":"5.6.2.0 Outpatient and early discharge policies Exclusive oral outpatient management for low-‍risk FN and an early discharge policy in low-‍risk cases that have become clinically stable, symptomatically better and with evidence of fever lysis after a minimum of 24 hours in hospital can be considered, provided that adequate understanding of the risks and surveillance are available at both the patient and family physician levels"
},
{
	"page":"ENAS5269_5.7.1.0",
	"text":"5.7.0.0 High-‍risk patients 5.7.1.0 Overview Admission and commencement of broad-‍spectrum IV antibiotics is recommended for patients with high-‍risk FN, according to MASCC criteria (< 21), or with high-‍risk features"
},
{
	"page":"ENAS5269_5.7.2.0",
	"text":"5.7.2.0 Choice of IV antibacterial Local epidemiological bacterial isolate and resistance patterns should help to determine first-‍choice empirical therapy Monotherapy (e.g. an anti-‍pseudomonal cephalosporin, such as ceftazidime or cefepime, imipenem, meropenem or piperacillin-‍tazobactam) and combination therapy generally have equivalent efficacy A ß-‍lactam antibiotic in combination with an aminoglycoside may be more appropriate for patients at high risk of prolonged neutropaenia and those with bacteraemia; namely in case of Pseudomonas aeruginosa-‍sepsis or in centres with known intermediate susceptibility of Gram-‍negative bacilli to ß-‍lactams Key recommendations for FN management are shown in the table here"
},
{
	"page":"ENAS5269_5.8.0.0",
	"text":"5.8.0.0 Key recommendations for FN management FN is observed in ± 1% of patients receiving chemotherapy; it is associated with considerable morbidity (20–30%) and mortality (10%) FN can be effectively prevented by the use of G-‍CSFs; it is recommended to use these agents in patients receiving chemotherapies with a > 20% risk of developing FN and in those having serious co-‍morbidities and/‍or aged > 60 years Patients with FN should be assessed for the risk of complications using a validated predictive tool, such as the MASCC score Patients with FN at a low risk of complications can often be treated with oral antibiotics and possibly as outpatients, if adequate follow-‍up is available Patients with FN at a high risk of complications should be hospitalised and treated without delay with broad spectrum antibiotics; these patients should be closely monitored for instability (pre-‍shock) FN, febrile neutropaenia; G-CSF, granulocyte-colony stimulating factor; MASCC, Multinational Association of Supportive Care in Cancer"
},
{
	"page":"ENAS5269_5.9.1.0",
	"text":"5.9.0.0 Specific indications for alternative therapy 5.9.1.0 Overview In specific situations, treatment durations may vary and local antibacterial guidelines should be followed"
},
{
	"page":"ENAS5269_5.9.2.0",
	"text":"5.9.2.0 Central IV catheters Catheter-‍related infection (CRI) should be suspected where there is an IV catheter Blood cultures from both the catheter and peripherally are required to allow determination of the differential time to positivity (DTTP) A DTTP of ± 2 hours is a highly sensitive and specific indicator of catheter-‍related bacteraemia When CRI is suspected, and the patient is stable, the catheter should not be removed without microbiological evidence of infection A glycopeptide, such as vancomycin, should be administered through the line when possible to cover Gram-‍positive organisms, with teicoplanin as a useful alternative, which can be administered once daily as a line lock Success in treating CRI without catheter removal depends on the blood culture pathogens isolated In coagulase-‍negative Staphylococcus associated CRT, catheter preservation can be attempted if the patient is stable Catheter retention does not affect the resolution of coagulase-negative Staphylococcus bacteraemia but is a significant risk factor for recurrence Removal of the line is indicated for tunnel infections, pocket infections (implanted port system), persistent bacteraemia despite adequate treatment, atypical mycobacterial infection and candidaemia For Staphylococcus aureus infections, the recommendation is to remove the line if at all possible, although careful management may allow it to be maintained for a short period Persistent fever and bacteraemia despite appropriate antibiotics are indications for line removal"
},
{
	"page":"ENAS5269_5.9.3.0",
	"text":"5.9.3.0 Pneumonia In the case of a clinical or radiological outpatient diagnosis of pneumonia, adding a macrolide or a fluoroquinolone antibiotic to a ß-‍lactam antibiotic can extend antibiotic cover to atypical organisms, such as Legionella and Mycoplasma Pneumocystis jirovecii infection should be considered in patients presenting with high respiratory rates and/‍or who desaturate readily off oxygen or on minimal exertion Predisposing factors include prior corticosteroid therapy, use of immune suppressants after organ transplantation, exposure to purine analogues and a lack of reliable co-‍trimoxazole chemoprophylaxis Early treatment with a mould-‍active antifungal agent is recommended in high-‍risk patients with profound prolonged neutropaenia and lung infiltrates"
},
{
	"page":"ENAS5269_5.9.4.0",
	"text":"5.9.4.0 Lung infiltrates Patients with acute myeloid leukaemia during remission induction chemotherapy and those undergoing allogeneic haematopoietic stem cell transplantation with prior conditioning ChT are at risk of invasive fungal infections (namely aspergillosis) due to prolonged and profound neutropaenia Frequent assessment of initial response to antibacterial therapy is essential and in the absence of prompt improvement, further investigations are warranted If invasive aspergillus is suspected, a same-‍day high-‍resolution chest computed tomography (CT) scan is recommended, looking for typical features such as nodules with halos or ground-‍glass change, and serum galacto-‍mannan should be measured If any infiltrate is found, bronchoalveolar lavage should be undertaken Involvement of an infectious diseases (ID) specialist or clinical microbiologist is recommended and appropriate therapy against infection with fungi or Pneumocystis species should be initiated Voriconazole or liposomal amphotericin B, combined with an echinocandin in unresponsive disease, are recommended for presumed aspergillosis (for cases with typical infiltrates on CT) A precise microbiological diagnosis is desirable in suspected invasive fungal infection to assess anti-‍fungal sensitivity High-‍dose co-‍trimoxazole is the treatment of choice for suspected Pneumocystis infection"
},
{
	"page":"ENAS5269_5.9.5.0",
	"text":"Vesicular lesions/suspected viral infection 5.9.5.0 Vesicular lesions/susp. viral infection Following sampling, therapy with aciclovir should be initiated, with substitution with ganciclovir (or foscarnet) only when there is a high suspicion of invasive cytomegalovirus infection"
},
{
	"page":"ENAS5269_5.9.6.0",
	"text":"5.9.6.0 Suspected meningitis or encephalitis Lumbar puncture (before institution of antibiotics if possible) is mandatory Ceftazidime plus ampicillin (to cover Listeria monocytogenes) or meropenem is recommended for bacterial meningitis A high dose of acyclovir is recommended for viral encephalitis"
},
{
	"page":"ENAS5269_5.9.7.0",
	"text":"5.9.7.0 Cellulitis The addition of vancomycin broadens cover against skin pathogens Linezolid and daptomycin are emerging alternatives to glycopeptides, although clinical experience is limited"
},
{
	"page":"ENAS5269_5.9.8.0",
	"text":"5.9.8.0 Intra-‍abdominal or pelvic sepsis Metronidazole is recommended where there is clinical or microbiological evidence of intra-‍abdominal or pelvic sepsis, unless the patient is receiving a carbapenem or piperacillin-‍tazobactam"
},
{
	"page":"ENAS5269_5.9.9.0",
	"text":"5.9.9.0 Diarrhoea Clostridium difficile presence should be investigated and, if suspected, treatment with oral vancomycin or metronidazole is recommended"
},
{
	"page":"ENAS5269_5.9.10.0",
	"text":"5.9.10.0 Candidiasis Candidaemia can be diagnosed on blood culture, although development of positivity may take several days Empirical initiation of antifungal therapy is recommended where fever fails to respond to 3–7 days of broad-‍spectrum antibiotics A CT scan of liver and spleen should be performed before commencing anti-Candida treatment Liposomal amphotericin B or an echinocandin antifungal, such as caspofungin, are appropriate first-‍line treatments if the patient has already been exposed to an azole or has non-‍albicans Candida Fluconazole can be given first line if the patient is at a low risk of invasive aspergillosis, there is a low local rate of azole-‍resistant Candida isolates and azole antifungal prophylaxis was not used Antifungal treatment should be continued until neutropaenia has resolved, or for at least 14 days in patients with a demonstrated invasive Candida infection Specific needs for preventing other opportunistic infections are required in patients with haematological malignancies, namely those undergoing haematopoietic stem cell transplants"
},
{
	"page":"ENAS5269_5.10.1.0",
	"text":"Daily follow-up and assessment of response 5.10.0.0 Daily follow-‍up and assess. of response 5.10.1.0 Overview Clinical assessment may be required every 2–4 hours in cases needing resuscitation Daily assessment of fever trends and bone marrow and renal function is indicated until the patient is afebrile and ANC ≥ 0.5 x 109/L for 24 hours, as shown here Repeated imaging may be required in patients with persistent pyrexia If the patient is afebrile and has an ANC ≥ 0.5 x 109/L at 48 hours, has low risk and no identified cause of infection, change to oral antibiotics can be considered In high-‍risk patients with no cause identified and on dual therapy, aminoglycoside may be discontinued, with initiation of appropriate specific therapy when the cause is found In patients still febrile at 48 hours, but clinically stable, initial antibacterial therapy should be continued In patients still febrile at 48 hours and clinically unstable, antibacterial therapy should be rotated or broadened, if justified by clinical developments Addition of a glycopeptide, or change to imipenem or meropenem and a glycopeptide, can be considered Persistent fever requires prompt advice from an ID physician or clinical microbiologist and consideration of unusual infections, particularly if C-‍reactive protein levels are elevated Imaging of the chest and upper abdomen can exclude probable fungal or yeast infection, or abscesses Empirical initiation of antifungal therapy may be required for pyrexia lasting > 4–6 days"
},
{
	"page":"ENAS5269_5.11.0.0",
	"text":"5.11.0.0 Duration of therapy If the ANC is ≥ 0.5 x 109/L, the patient is asymptomatic and has been afebrile for 48 hours and blood cultures are negative, antibacterials can be discontinued If the ANC is < 0.5 x 109/L, the patient has suffered no complications and has been afebrile for 5–7 days, antibacterials can be discontinued except in certain high-‍risk cases with acute leukaemia and following high-‍dose chemotherapy, when antibacterials are often continued for up to 10 days, or until the ANC is ≥ 0.5 x 109/L Patients with persistent fever despite neutrophil recovery should be assessed by an ID physician or clinical microbiologist and antifungal therapy considered"
},
{
	"page":"ENAS5269_6.1.0.0",
	"text":"6.0.0.0 Summary of recommendations 6.1.0.0 Introduction FN is defined as an oral temperature of > 38.3°C or two consecutive readings of > 38.0°C for 2 hours and an ANC < 0.5 x 109/L, or expected to fall below 0.5 x 109/L Factors increasing the risk of FN and its complications include: older age, advanced disease, history of prior FN, no antibiotic prophylaxis or G-CSF use, mucositis, poor PS and/‍or cardiovascular disease These guidelines should be used alongside appropriate local antimicrobial policies adapted to the centre’s epidemiology"
},
{
	"page":"ENAS5269_6.2.0.0",
	"text":"6.2.0.0 CHEMOPROPHYLAXIS The use of antimicrobials, including fluoroquinolones, in prophylaxis is discouraged EORTC and ASCO guidelines recommend the restriction of antibacterial prophylaxis to patients at high risk for FN"
},
{
	"page":"ENAS5269_6.3.1.0",
	"text":"6.3.0.0. Indications for primary prophylaxis with G-CSF 6.3.1.0 Overview INDICATIONS FOR PRIMARY PROPHYLAXIS OF FN WITH G-CSF Primary prophylaxis with G-CSF is recommended if the risk of FN is > 20% for all planned cycles of treatment For patients with an intermediate FN risk (10–20%), age and existing co-morbidities are important considerations in prophylaxis decisions G-CSF can also be considered for patients with reduced bone marrow reserve due to extensive radiotherapy or those neutropaenic in the context of HIV infection Secondary prophylaxis is indicated if dose reduction below threshold or delay of ChT is not desirable The most common G-‍CSF-‍related adverse effect is minor or moderate bone pain"
},
{
	"page":"ENAS5269_6.3.2.0",
	"text":"6.3.2.0 Dose, sched. & route of G-CSF & pegfilgrastim Dose, schedule and route of application of G-CSF and pegfilgrastim The recommended doses and schedules are G-CSF 5 μg/‍kg/‍day SC 24–72 hours after the last day of ChT until sufficient/‍stable post-‍nadir ANC recovery (achieving target ANC > 10 × 109/L is not necessary) Pegfilgrastim (SC) as a single 100 μg/kg dose (individualised) or a 6 mg total dose (general approach) Filgrastim 5 μg/‍kg/‍day for approximately 10 days There are no adequate data to support reduced numbers of days or alternate days of G-CSF, or for use on day 1 instead of day 2"
},
{
	"page":"ENAS5269_6.4.1.0",
	"text":"6.4.0.0 MANAGEMENT OF FN 6.4.1.0 Patient education and local policies Outpatients should be educated to monitor their symptoms, including body temperature, and should be provided with clear written instructions on when and how to contact the appropriate service in the event of concerns Effective written local policies are essential along with protocols for the management of FN in patients presenting to the Emergency Department Initial therapy should be given in the hospital within 1 hour from the admission of a patient with FN Local epidemiological knowledge is crucial"
},
{
	"page":"ENAS5269_6.4.2.0",
	"text":"6.4.2.0 Initial assessment and investigations A detailed history should include the nature of the ChT, prior prophylactic antibiotics, concomitant steroid use, recent surgical procedures and presence of allergies and investigation of past positive microbiology is recommended An initial assessment of circulatory and respiratory function, with vigorous resuscitation where necessary, should be followed by careful examination for potential foci of infection Signs and symptoms of infection in neutropaenic patients can be minimal, particularly in those receiving corticosteroids, or in elderly patients Vigilance is required in patients at risk of FN who present unwell, are hypotensive (compared with the known previous blood pressure readings) and have a low grade temperature or are afebrile, as this may be an indication of Gram-‍negative septicaemia Urgent full blood counts are crucial Two sets of blood cultures from a peripheral vein and any indwelling venous catheters should be taken along with specimens for microbiological testing from any suspected sites of infection, before the prompt institution of empirical broad-‍spectrum antimicrobial therapy Urinary tract infections should be suspected, even in asymptomatic patients with a past history of such infections"
},
{
	"page":"ENAS5269_6.4.3.0",
	"text":"6.4.3.0 Outcome risk assessment The MASCC index allows rapid clinical assessment of risk, with low-‍risk cases indicated by a score ≥ 21 If an obvious focus of infection is apparent, antibacterials should be tailored accordingly"
},
{
	"page":"ENAS5269_6.4.4.1",
	"text":"6.4.4.0 Low-‍risk patients 6.4.4.1 Oral therapy Inpatient oral antibacterial therapy can be safely substituted for conventional IV treatment in some low-‍risk FN patients, namely those who are haemodynamically stable, without acute leukaemia or evidence of organ failure and without pneumonia, an indwelling venous catheter or severe soft tissue infection Combination therapy (quinolone with amoxicillin plus clavulanic acid) is preferred to single-‍agent quinolones Oral quinolone therapy should not be used in patients who have undergone quinolone prophylaxis Early change to oral combinations in afebrile patients after 48 hours on IV therapy is safe Some low-‍risk patients may be treated with outpatient parenteral regimens"
},
{
	"page":"ENAS5269_6.4.4.2",
	"text":"6.4.4.2 Outpatient and early discharge policies Exclusive oral outpatient management for low-‍risk FN and an early discharge policy in low-‍risk cases that have become clinically stable, symptomatically better and with evidence of fever lysis after a minimum of 24 hours in hospital can be considered"
},
{
	"page":"ENAS5269_6.4.5.1",
	"text":"6.4.5.0 High-‍risk patients 6.4.5.1 Overview Admission and commencement of broad-‍spectrum IV antibiotics is recommended for patients with high-‍risk FN (MASCC score < 21) or with high-‍risk features"
},
{
	"page":"ENAS5269_6.4.5.2",
	"text":"6.4.5.2 Choice of IV antibacterial Local epidemiological bacterial isolate and resistance patterns should help to determine first-‍choice empirical therapy Monotherapy (e.g. an anti-‍pseudomonal cephalosporin, such as ceftazidime or cefepime, imipenem, meropenem or piperacillin-‍tazobactam) and combination therapy generally have equivalent efficacy A ß-‍lactam/aminoglycoside combination may be appropriate for patients at high risk of prolonged neutropaenia and those with bacteraemia"
},
{
	"page":"ENAS5269_6.4.6.1",
	"text":"6.4.6.0 Specific indications for alternative therapy 6.4.6.1 Overview Local antibacterial guidelines should be followed"
},
{
	"page":"ENAS5269_6.4.6.2",
	"text":"6.4.6.2 Central IV catheters CRI should be suspected where there is an IV catheter Blood cultures from both the catheter and peripherally are required and a DTTP of ± 2 hours is an indication of catheter-‍related bacteraemia When CRI is suspected and the patient is stable, the catheter should not be removed without microbiological evidence of infection; a glycopeptide, such as vancomycin, should be administered through the line, with teicoplanin (once daily as a line lock) as a useful alternative In coagulase-negative Staphylococcus-associated CRT, catheter preservation can be attempted if the patient is stable Catheter retention does not affect coagulase-negative Staphylococcus bacteraemia resolution but is a significant risk factor for recurrence Line removal is indicated for tunnel infections, pocket infections (implanted port system), persistent bacteraemia despite adequate treatment, atypical mycobacterial infection and candidaemia For S. aureus infections, immediate line removal is recommended, although careful management may allow it to be maintained for a short period Persistent fever and bacteraemia despite appropriate antibiotics are indications for line removal"
},
{
	"page":"ENAS5269_6.4.6.3",
	"text":"6.4.6.3 Pneumonia In the case of a clinical or radiological outpatient diagnosis of pneumonia, adding a macrolide or a fluoroquinolone antibiotic to a ß-‍lactam antibiotic can extend antibiotic cover to atypical organisms, such as Legionella and Mycoplasma Pneumocystis jirovecii infection should be considered in patients presenting with high respiratory rates and/‍or who desaturate readily off oxygen or on minimal exertion Early treatment with a mould-‍active antifungal agent is recommended in high-‍risk patients with profound prolonged neutropaenia and lung infiltrates"
},
{
	"page":"ENAS5269_6.4.6.4",
	"text":"6.4.6.4 Lung infiltrates Frequent assessment of initial response to antibacterial therapy is essential and in the absence of prompt improvement, further investigations are warranted If invasive aspergillus is suspected, a same-‍day high-‍resolution chest CT scan is recommended and serum galacto-‍mannan should be measured Bronchoalveolar lavage is recommended on detection of infiltrates Involvement of an ID specialist or clinical microbiologist is recommended and appropriate therapy against infection with fungi or Pneumocystis species should be initiated Voriconazole or liposomal amphotericin B, combined with an echinocandin in unresponsive disease, are recommended for presumed aspergillosis (for cases with typical infiltrates on CT) A precise microbiological diagnosis is desirable in suspected invasive fungal infection to assess anti-‍fungal sensitivity High-‍dose co-‍trimoxazole is the treatment of choice for suspected Pneumocystis infection"
},
{
	"page":"ENAS5269_6.4.6.5",
	"text":"6.4.6.5 Vesicular lesions/susp. viral infection Vesicular lesions/suspected viral infection Following sampling, aciclovir should be initiated, with substitution with ganciclovir (or foscarnet) only when there is a high suspicion of invasive cytomegalovirus infection"
},
{
	"page":"ENAS5269_6.4.6.6",
	"text":"6.4.6.6 Suspected meningitis or encephalitis Lumbar puncture (before institution of antibiotics if possible) is mandatory Ceftazidime plus ampicillin (to cover Listeria monocytogenes) or meropenem is recommended for bacterial meningitis A high dose of acyclovir is recommended for viral encephalitis"
},
{
	"page":"ENAS5269_6.4.6.7",
	"text":"6.4.6.7 Cellulitis The addition of vancomycin broadens cover against skin pathogens Linezolid and daptomycin are emerging alternatives to glycopeptides"
},
{
	"page":"ENAS5269_6.4.6.8",
	"text":"6.4.6.8 Intra-‍abdominal or pelvic sepsis Metronidazole is recommended where there is clinical or microbiological evidence of intra-‍abdominal or pelvic sepsis, unless the patient is receiving a carbapenem or piperacillin-‍tazobactam"
},
{
	"page":"ENAS5269_6.4.6.9",
	"text":"6.4.6.9 Diarrhoea Oral vancomycin or metronidazole is recommended for suspected Clostridium difficile infection"
},
{
	"page":"ENAS5269_6.4.6.10",
	"text":"6.4.6.10 Candidiasis Candidaemia can be diagnosed on blood culture Empirical initiation of antifungal therapy is recommended where fever fails to respond to 3–7 days of broad-‍spectrum antibiotics A CT scan of liver and spleen should be performed before commencing anti-Candida treatment Liposomal amphotericin B or an echinocandin antifungal, such as caspofungin, are appropriate first-‍line treatments if the patient has already been exposed to an azole or has non-‍albicans Candida Fluconazole can be given first line if the patient is at a low risk of invasive aspergillosis, there is a low local rate of azole-‍resistant Candida isolates and azole antifungal prophylaxis was not used Antifungal treatment should be continued until neutropaenia has resolved, or for at least 14 days in patients with a demonstrated invasive Candida infection"
},
{
	"page":"ENAS5269_6.4.7.0",
	"text":"6.4.7.0 Daily follow-‍up and assess. of response Daily follow-up and assessment of response Clinical assessment may be required every 2–4 hours in cases needing resuscitation Daily assessment of fever trends and bone marrow and renal function is indicated until the patient is afebrile and ANC ≥ 0.5 x 109/L for 24 hours Repeated imaging may be required in patients with persistent pyrexia If the patient is afebrile and has an ANC ≥ 0.5 x 109/L at 48 hours, has low risk and no identified cause of infection, change to oral antibiotics can be considered In high-‍risk patients with no cause identified and on dual therapy, aminoglycoside may be discontinued, with initiation of appropriate specific therapy when the cause is found In patients still febrile at 48 hours, but clinically stable, initial antibacterial therapy should be continued In patients still febrile at 48 hours and clinically unstable, antibacterial therapy should be rotated or broadened, with consideration given to addition of a glycopeptide, or change to imipenem or meropenem and a glycopeptide Persistent fever requires prompt advice from an ID physician or clinical microbiologist and consideration of unusual infections and chest and upper abdominal imaging can exclude probable fungal or yeast infection, or abscesses Empirical initiation of antifungal therapy may be required for pyrexia lasting > 4–6 days"
},
{
	"page":"ENAS5269_6.4.8.0",
	"text":"6.4.8.0 Duration of therapy If the ANC is ≥ 0.5 x 109/L, the patient is asymptomatic and has been afebrile for 48 hours and blood cultures are negative, antibacterials can be discontinued If the ANC is < 0.5 x 109/L, the patient has suffered no complications and has been afebrile for 5–7 days, antibacterials can be discontinued except in certain high-risk cases with acute leukaemia and following high-‍dose chemotherapy, when antibacterials are often continued for up to 10 days, or until the ANC is ≥ 0.5 x 109/L Patients with persistent fever despite neutrophil recovery should be assessed by an ID physician or clinical microbiologist and antifungal therapy considered"
},
{
	"page":"ENAS5269_7.0.0.0",
	"text":"5-FU 5-‍fluorouracil 5-HT 5-‍hydroxytryptamine Ab antibiotic ABC Airway, Breathing and Circulation ABLC amphotericin B lipid complex AC anthracycline/‍cyclophosphamide ACCP American College of Chest Physicians ACE angiotensin converting enzyme AChR acetylcholine receptor ACTH adrenocorticotropic hormone ADL activities of daily living ADR adverse drug reaction AE adverse event AFSOS Association Francophone pour les Soins Oncologiques de Support ALT antibiotic lock therapy ANA antinuclear antibody ANC absolute neutrophil count ANCA anti-neutrophil cytoplasmic antibody aPTT activated partial thromboplastin time ARB angiotensin receptor blocker ARDS acute respiratory distress syndrome ASA 5-‍acetyl salicylic acid ASCO American Society of Clinical Oncology AST antimicrobial susceptibility testing ATB antibiotic BAL bronchoalveolar lavage ATG anti-thymocyte globulin BB beta-‍blocking agents BCoG bacitracin/‍clotrimazole/‍gentamicin bid twice daily bid M/W/F twice daily Monday/Wednesday/Friday BNP brain natriuretic peptides BP blood pressure BSA body surface area BSI blood stream infection C Candida Ca calcium CFU colony-‍forming unit CHF congestive heart failure ChT chemotherapy CINV chemotherapy-induced nausea and vomiting CLL chronic lymphocytic leukaemia CMV cytomegalovirus CNS coagulase-‍negative Staphylococcus CPGs Clinical Practice Guidelines CrCl creatinine clearance CRBSI catheter-‍related blood stream infection CRI catheter-‍related infection CRP C-‍reactive protein CRS cytokine-release syndrome CRT chemoradiotherapy CT computed tomography CTCAE Common Terminology Criteria of Adverse Events CTLA4 cytotoxic T lymphocyte-associated protein 4 CV cardiovascular CVA cerebrovascular accident CVAD central venous access device CVC central venous catheter CYP cytochrome P450 DADS diffuse alveolar damage syndrome DDx differential diagnosis DEX dexamethasone DM diabetes mellitus DMSO dimethyl sulfoxide DRESS drug rash with eosinophilia and systemic symptoms DT deceleration time of the early peak flow DTTP differential time to positivity DVH dose volume histogram DVT deep vein thrombosis DW dextrose water E Enterococcus E/A ratio ratio of early peak flow velocity to atrial peak flow velocity ECG electrocardiogram ECHO echocardiography EDTA ethylenediaminetetraacetate EGFR epidermal growth factor receptor EMA European Medicines Agency EMG electromyography EORTC European Organisation for Research and Treatment of Cancer ESBL Enterococcus Staphylococci Extended spectrum ß-‍lactamase ESMO European Society for Medical Oncology ESR erythrocyte sedimentation rate FBC full blood count FDA Food and Drug Administration FN febrile neutropaenia FSH follicle-stimulating hormone FT4 free thyroxine GAD glutamic acid decarboxylase GBM glomerular basement membrane GBS Guillain-Barré syndrome G-CSF granulocyte-‍colony stimulating factor GI gastrointestinal GM-‍CSF granulocyte-‍macrophage colony-‍stimulating factor GN glomerulonephritis GNB Gram-‍negative bacillus Hb haemoglobin HER2 human epidermal growth factor 2 HIV human immunodeficiency virus HNC head and neck cancer HRT hormone replacement therapy HSCT haematopoietic stem cell transplantation HSR hypersensitivity reaction HSV herpes simplex virus ICPi immune checkpoint inhibitor ID infectious diseases Ig immunoglobulin IgE immunoglobulin E IGF1 insulin-like growth factor 1 IgG immunoglobulin G IM intramuscular IMRT intensity-‍modulated radiotherapy INR international normalised ratio IR infusion reaction irAE immune-related adverse event ISOO International Society of Oral Oncology IV intravenous IVIg intravenous immunoglobulin IVRT isovolumic relaxation time K potassium KGF-1 keratinocyte growth factor-1 LCI lung clearance index LDH lactate dehydrogenase LFT liver function test LH luteinising hormone LKM liver kidney microsomal LLN lower limit of normal LMWH low molecular weight heparin LVD left ventricular dysfunction LVEF left ventricular ejection fraction M/C/S microscopy, culture and susceptibility MASCC Multinational Association of Supportive Care in Cancer MDR multi-‍drug resistant MEC moderately emetogenic chemotherapy MHD maximum heart distance mIAS mTOR inhibitor-‍associated stomatitis MIC minimum inhibitory concentration MMF mycophenolate mofetil MoAb monoclonal antibody MRA magnetic resonance angiogram MRI magnetic resonance imaging MRSA methicillin-resistant S. aureus mTOR mechanistic target of rapamycin MUGA multiple gated acquisition MuSK muscle-specific kinase Mx management n/a not available NaCl sodium chloride NCCN National Comprehensive Cancer Network NCI-‍CTCAE National Cancer Institute-Common Terminology Criteria for Adverse Events NCS/EMG nerve conduction studies/electromyography NEG negative NK neurokinin NS normal saline NSAID non-‍steroidal anti-‍inflammatory drug NSCLC non-small-cell lung cancer NTCP normal tissue complication probability NYHA New York Heart Association od once daily ONS Oncology Nursing Society OS overall survival P pseudomonas PCR polymerase chain reaction PD-1 programmed death 1 PD-L1 programmed death ligand 1 PE pulmonary embolism PICC peripherally inserted central catheter PJP Pneumocystis jiroveci pneumonia POS positive PS performance status PTA polymyxin/tobramycin/amphotericin B PTV planning target volume QTc QT interval corrected for heart rate RA receptor agonist RINV radiotherapy-induced nausea and vomiting RT radiotherapy S Staphylococcus SC subcutaneous SCT stem cell transplantation SFNEP Société Francophone Nutrition Clinique et Métabolique SLA/LP soluble liver antigen/liver-pancreas antibody SMA smooth muscle autoantibody SOR Standards, Options and Recommendations methodology spp species SVC superior vena cava T3 triiodothyronine T4 thyroxine TB tuberculosis TBI total body irradiation TCLO transfer factor for carbon monoxide tds three times a day TEE trans-‍oesophageal echocardiogram TKI tyrosine kinase inhibitor TMP-‍SMZ trimethoprim–sulfamethoxazole TNFα tumour necrosis factor alpha TnI troponin tPA tissue plasminogen activator TPN total parenteral nutrition TPO thyroid peroxidase TSH thyroid-stimulating hormone U unit UEC urea, electrolytes, creatinine UFH unfractionated heparin ULN upper limit of normal UPCR urine protein to creatinine ratio US ultrasound VATS video-assisted thoracoscopic surgery VEGF vascular endothelial growth factor VEGFR vascular endothelial growth factor receptor VHNSS Vanderbilt Head and Neck Symptom Survey VitD vitamin D VKA vitamin K antagonist VTE venous thromboembolism WBC white blood cell WHO World Health Organization"
}
]